Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled double-blind trial of JNJ-54175446 in major depressive disorder with incomplete antidepressant response and inflammatory biomarker profile
2018-001884-21Phase 2Unknown
- Sponsor
- Cambridgeshire and Peterborough NHS Foundation Trust
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-54175446 with Placebo (2 arms). Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale total score at week 8. Status: unknown.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-001884-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001884-21.